Mechanism of action and clinical activity of tasquinimod in castrate-resistant prostate cancer

OncoTargets and Therapy

Volumn 7, Issue , 2014, Pages 223-234

  Gupta, Neha ^a   Ustwani, Omar Al ^a   Shen, Li ^a   Pili, Roberto ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

ABR 215050; Castration resistant; Prostate adenocarcinoma; Quinoline 3 carboxamide

Indexed keywords

EID: 84894247854     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: 10.2147/OTT.S53524     Document Type: Article

References (58)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11-30.
2. Hotte SJ, Saad F. Current management of castrate-resistant prostate cancer. Curr Oncol. 2010;17 Suppl 2:S72-S79.
3. Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26:1148-1159.
4. Cheng HH. Advanced Clinical States in Prostate Cancer. In: Kibel AS, editor. Urologic Clinics of North America; 2012.
5. Heidenreich A, Schrader AJ. The treatment of hormone refractory prostate cancer. EAU Update Series. 2003;1:40-50.
6. Petrylak DP. The treatment of hormone-refractory prostate cancer: docetaxel and beyond. Rev Urol. 2006;8 Suppl 2:S48-S55.
7. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513-1520.
8. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502-1512.
9. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187-1197.
10. Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368: 138-148.
11. Hafeez S, Parker C. Radium-223 for the treatment of prostate cancer. Expert Opin Investig Drugs. 2013;22:379-387.
12. Isaacs JT. The long and winding road for the development of tasquinimod as an oral second-generation quinoline-3-carboxamide antiangiogenic drug for the treatment of prostate cancer. Expert Opin Investig Drugs. 2010;19:1235-1243.
13. Olsson A, Bjork A, Vallon-Christersson J, et al. Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors. Mol Cancer. 2010;9:107.
14. Stalhandske T, Eriksoo E, Sandberg B. A novel quinoline-3-carboxamide with interesting immunomodulatory activity. Int J Immunopharmacol. 1982;4:336. Available from: http://www.sciencedirect.com/science/article/pii/0192056182903125. Accessed January 8, 2014.
15. Harning R, Szalay J. A treatment for metastasis of murine ocular melanoma. Invest Ophthalmol Vis Sci. 1988;29:1505-1510.
16. Kalland T. Effects of the immunomodulator LS 2616 on growth and metastasis of the murine B16-F10 melanoma. Cancer Res. 1986;46:3018-3022.
17. Joseph IB, Vukanovic J, Isaacs JT. Antiangiogenic treatment with linomide as chemoprevention for prostate, seminal vesicle, and breast carcinogenesis in rodents. Cancer Res. 1996;56:3404-3408.
18. Hartley-Asp B, Vukanovic J, Joseph IB, et al. Anti-angiogenic treatment with linomide as adjuvant to surgical castration in experimental prostate cancer. J Urol. 1997;158:902-907.
19. Tan IL, Lycklama a Nijeholt GJ, Polman CH, et al. Linomide in the treatment of multiple sclerosis: MRI results from prematurely terminated Phase-III trials. Mult Scler. 2000;6:99-104.
20. Brunmark C, Runstrom A, Ohlsson L, et al. The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis. J Neuroimmunol. 2002;130:163-172.
21. Isaacs JT, Pili R, Qian DZ, et al. Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer. Prostate. 2006;66:1768-1778.
22. Bratt O, Haggman M, Ahlgren G, et al. Open-label, clinical Phase I studies of tasquinimod in patients with castration-resistant prostate cancer. Br J Cancer. 2009;101:1233-1240.
23. Pili R, Haggman M, Stadler WM, et al. Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. J Clin Oncol. 2011;29:4022-4028.
24. Diab A, Michael L, Wahren B, et al. Linomide suppresses acute experimental autoimmune encephalomyelitis in Lewis rats by counter-acting the imbalance of pro-inflammatory versus anti-inflammatory cytokines. J Neuroimmunol. 1998;85:146-154.
25. Dalrymple SL, Becker RE, Isaacs JT. The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts. Prostate. 2007;67:790-797.
26. Vukanovic J, Hartley-Asp B, Isaacs JT. Inhibition of tumor angiogenesis and the therapeutic ability of linomide against rat prostatic cancers. Prostate. 1995;26:235-246.
27. Jennbacken K, Welen K, Olsson A, et al. Inhibition of metastasis in a castration resistant prostate cancer model by the quinoline-3-carboxamide tasquinimod (ABR-215050). Prostate. 2012;72:913-924.
28. Weidner N, Carroll PR, Flax J, et al. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol. 1993;143: 401-409.
29. Gettman MT, Pacelli A, Slezak J, et al. Role of microvessel density in predicting recurrence in pathologic Stage T3 prostatic adenocarcinoma. Urology. 1999;54:479-485.
30. Doll JA, Reiher FK, Crawford SE, et al. Thrombospondin-1, vascular endothelial growth factor and fibroblast growth factor-2 are key functional regulators of angiogenesis in the prostate. Prostate. 2001;49: 293-305.
31. Rodriguez-Manzaneque JC, Lane TF, Ortega MA, et al. Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor. Proc Natl Acad Sci U S A. 2001;98: 12485-12490.
32. Ren B, Yee KO, Lawler J, et al. Regulation of tumor angiogenesis by thrombospondin-1. Biochim Biophys Acta. 2006;1765:178-188.
33. Du R, Lu KV, Petritsch C, et al. HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell. 2008;13:206-220.
34. Lee NV, Sato M, Annis DS, et al. ADAMTS1 mediates the release of antiangiogenic polypeptides from TSP1 and 2. EMBO J. 2006;25: 5270-5283.
35. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol. 2002;20:4368-4380.
36. Martin-Manso G, Galli S, Ridnour LA, et al. Thrombospondin 1 promotes tumor macrophage recruitment and enhances tumor cell cytotoxicity of differentiated U937 cells. Cancer Res. 2008;68:7090-7099.
37. Bjork P, Bjork A, Vogl T, et al. Identification of human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamides. PLoS Biol. 2009;7:e97.
38. Sinha P, Okoro C, Foell D, et al. Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. J Immunol. 2008;181:4666-4675.
39. Schmid MC, Varner JA. Myeloid cells in the tumor microenvironment: modulation of tumor angiogenesis and tumor inflammation. J Oncol. 2010;2010:201026.
40. Sevko A, Umansky V. Myeloid-derived suppressor cells interact with tumors in terms of myelopoiesis, tumorigenesis and immunosuppression: thick as thieves. J Cancer. 2013;4:3-11.
41. Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol. 2009;182:4499-4506.
42. Ye XZ, Yu SC, Bian XW. Contribution of myeloid-derived suppressor cells to tumor-induced immune suppression, angiogenesis, invasion and metastasis. J Genet Genomics. 2010;37:423-430.
43. Shen L, Ciesielski M, Miles KM, et al. Targeting myeloid derived suppressor cells as novel strategy to enhance immunotherapy in murine prostate cancer models. [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 1551. doi:1538-7445.AM2012-1551. Available from: http://cancerres.aacrjournals.org/cgi/content/short/72/8_MeetingAbstracts/1551.
44. Cheng P, Corzo CA, Luetteke N, et al. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J Exp Med. 2008;205:2235-2249.
45. Shen L, Ciesielski M, Miles KM, et al. Modulation of suppressive myeloid populations by tasquinimod. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 4746. doi:10.1158/1538-7445.AM2013-4746. Available from: http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/73/8_MeetingAbstracts/4746.
46. Taichman RS, Cooper C, Keller ET, et al. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res. 2002;62:1832-1837.
47. Erler JT, Bennewith KL, Cox TR, et al. Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell. 2009;15:35-44.
48. Vanhara P, Hampl A, Kozubik A, et al. Growth/differentiation factor-15: prostate cancer suppressor or promoter? Prostate Cancer Prostatic Dis. 2012;15:320-328.
49. Husaini Y, Qiu MR, Lockwood GP, et al. Macrophage inhibitory cytokine-1 (MIC-1/GDF15) slows cancer development but increases metastases in TRAMP prostate cancer prone mice. PLoS One. 2012;7:e43833.
50. Whitson RJ, Lucia MS, Lambert JR. Growth differentiation factor-15 (GDF-15) suppresses in vitro angiogenesis through a novel interaction with connective tissue growth factor (CCN2). J Cell Biochem. 2013;114(6):1424-1433.
51. Beresford AP. CYP1A1: friend or foe? Drug Metab Rev. 1993;25: 503-517.
52. Nandekar PP, Sangamwar AT. Cytochrome P450 1A1-mediated anticancer drug discovery: in silico findings. Expert Opin Drug Discov. 2012;7:771-789.
53. Keating GM. Cabazitaxel: a guide to its use in hormone-refractory metastatic prostate cancer. Drugs Aging. 2013;30(5):359-365.
54. Heidenreich A, Scholz HJ, Rogenhofer S, et al. Cabazitaxel plus prednisone for metastatic castration-resistant prostate cancer progressing after docetaxel: results from the german compassionate-use programme. Eur Urol.2013;63(6):977-982.
55. Armstrong AJ. The CATCH prostate cancer trial: cabazitaxel and tasquinimod in men with prostate cancer. Available from: http://clinicaltrials.gov/show/NCT01513733. NLM identifier: NCT01513733. Accessed November 22, 2013.
56. Dalrymple SL, Becker RE, Zhou H, et al. Tasquinimod prevents the angiogenic rebound induced by fractionated radiation resulting in an enhanced therapeutic response of prostate cancer xenografts. Prostate. 2012;72:638-648.
57. Active Biotech AB. A study of tasquinimod in men with metastatic castrate resistant prostate cancer. Available from: http://clinicaltrials.gov/show/NCT01234311. NLM identifier: NCT01234311. Accessed November 22, 2013.
58. Ipsen. A proof of concept study of maintenance therapy with tasquinimod in patients with metastatic castrate-resistant prostate cancer who are not progressing after a first line docetaxel based chemotherapy. Available from: http://clinicaltrials.gov/show/NCT01732549. NLM identifier: NCT01732549. Accessed November 22, 2013.